Dec 3 (Reuters) - Biogen expects growth of its keenly
watched Alzheimer's disease drug, Leqembi, to see a "linear
trend" in the United States in the near term, a company
executive said at a healthcare conference on Tuesday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini
Ganguli)